Equillium Inc
Equillium Inc (EQ) Covered Calls
Equillium Inc trades in the Biotechnology industry with an IV Rank of 85.32%, high versus the past year. EQ's highest covered call setup is the $5.00 strike expiring Apr 16, 2027, sorted by theoretical annualized return. It's 275.94% out of the money with 162 days to expiration, a 279.70% return until expiration, and a 630.19% theoretical annualized return. Across the setups shown, annualized returns run from 206.67% to 630.19% at strikes between $2.50 and $5.00, with 162 to 162 days to expiration, as of Nov 5, 2026.
Read more
Running EQ covered calls helps you generate income from Equillium Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best EQ covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If EQ stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling EQ covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given EQ covered call is worth writing.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases.
| 2027-04-16 | 162 | 5.00 | 275.94 | 0.05 | 1.00 | 372.00 | 279.70 | 630.19 | -3.76 | +0.58 | 15 | 0.95 |
| 2027-04-16 | 162 | 2.50 | 87.97 | 0.05 | 1.50 | 122.00 | 91.73 | 206.67 | -3.76 | +0.76 | 23 | 1.45 |
As of Nov 5, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank85.32% High
- Market cap (M$)82
- 52 weeks high-63.56%
- 52 weeks low69.74%
- Analyst recommendationStrong Buy
1.00 - Target price$8.60
566.67% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-0.18
- EPS growth next 5 years11.67%
As of Nov 13, 2026